Alta Schutte

About Professor Alta Schutte

Co-Director, Global Cardiovascular Program

  • Program Head, Blood Pressure Research
  • SHARP Professor and Principal Theme Lead: Cardiac, Vascular and Metabolic Medicine, UNSW Sydney

Alta Schutte is a SHARP Professor and Theme Lead for Cardiac, Vascular and Metabolic Medicine at UNSW Sydney; and Professorial Fellow at The George Institute Australia. She holds honorary appointments at the North-West University and University of the Witwatersrand in South Africa. She is the Past President of the International Society of Hypertension, Company Secretary of the Australian Cardiovascular Alliance, and Co-Chair of the Australian National Hypertension Taskforce.

Alta is a leading researcher with extensive experience in clinical trials and population-based studies in the field of blood pressure, hypertension and cardiovascular health. She has been the Chief Investigator of several multidisciplinary studies, published >450 papers in the field, and supervised over 85 postgraduate students. She is Chief Investigator of several Australian-funded trials and is a NHMRC Investigator Grant Leadership Fellow.

She is involved in numerous international consortia, such as the Global Burden of Disease study, the NCD Risk Factor Collaboration, May Measurement Month global blood pressure screening campaign, World Health Organization working groups and the Lancet Commission of Hypertension. She is the senior author of the 2020 International Society of Hypertension Global Hypertension Guidelines. She is Associate Editor of the journal, Hypertension, and has received numerous international awards for her work, most recently the 2022 American Heart Association’s Harriet Dustan Award, and 2023 Peter Sleight Excellence Award in Hypertension Clinical Research from the World Hypertension League.

Factors affecting hospital inpatient blood pressure measurement as ranked by a Delphi survey

Scientific Reports Date published:

How Accurate Is Inpatient Blood Pressure Measurement?

Hypertension Date published:

26-A-15266-ACC POOLED SAFETY ANALYSIS OF ZILEBESIRAN, AN INVESTIGATIONAL LONG-ACTING RNA INTERFERENCE THERAPEUTIC, FROM PHASE 2 STUDIES IN PATIENTS WITH HYPERTENSION

JACC Date published:

Uptake and Costs of the 60-Day Dispensing Policy for Antihypertensive Medicines in Australia: A Mixed Methods Study

Medical Journal of Australia Date published:

Related Readings